Fruit-Derived Compounds Inhibit Amyloid Beta Production via Molecular Docking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current research on Alzheimer's disease lacks effective therapeutic strategies to prevent amyloid beta (1-42) self-aggregation and deposition, and to modify the action of Gamma Secretase and Amyloid Precursor Protein (APP) to inhibit amyloid beta production, due to the complexity of the disease and limited understanding of the mechanism of action of potential compounds.
Innovation Solution
Identification and testing of specific Trihydroxyflavone, Retinoid, and Stilbene derivatives such as Rhamnetin, N-retinylidene-N-retinylethanolamine, Rosyrane, and Resveratrol for their ability to bind with Gamma Secretase and APP, using Molecular Docking and Molecular Dynamics to form stable complexes and inhibit APP degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If molecular docking and molecular dynamics are used to identify and test compounds for binding with Gamma Secretase and APP, then the precision of identifying effective compounds is improved, but the complexity of the research process increases
Solution Approach 1:
The patent replaces complex in-vitro and in-vivo experimental systems with computer-based molecular docking and molecular dynamics simulations. This substitution allows for precise identification of compound-protein binding interactions without the need for complex laboratory infrastructure, animal models, or cellular assays, thereby improving precision while reducing overall system complexity.
Solution Approach 2:
The patent creates digital copies of the protein structures (Gamma Secretase and APP) and compounds through computational modeling. These virtual models allow for repeated testing and analysis without the limitations of physical experimental systems, enabling precise identification of binding interactions through simulated molecular interactions rather than physical experimentation.
2Adaptability or versatility
If multiple compound classes (Trihydroxyflavone, Retinoid, Stilbene) are screened for binding activity, then the versatility of potential therapeutic compounds is improved, but the quantity of compounds to be tested increases
Solution Approach 1:
The patent identifies three compound classes (Trihydroxyflavone, Retinoid, Stilbene) that each have the universal capability to bind with both Gamma Secretase and APP, the two primary targets for Alzheimer's therapy. This multi-functionality approach allows a single screening process to evaluate compounds for dual target engagement, improving versatility while managing the quantity of compounds through class-based organization.
Solution Approach 2:
The patent organizes the large number of compounds to be tested into three distinct chemical classes with different structural parameters and binding mechanisms. By grouping compounds according to their chemical parameters and known binding characteristics, the research can systematically evaluate each class's potential without treating every compound as a completely separate entity, thereby managing quantity while maintaining versatility.
Data Source
AI summary
The computer guided digital platform screened out test compounds in a cell free system using Molecular Docking and Molecular Dynamics. The experimental outcomes demonstrate complex structure formation between the test compounds Rhamnetin, Rosyrane, N-retinylidene-N-retinylethanolamine, Hesperidin, Trihydroxybutyrate, Trihydroxyflavone, Arylaminoethylamide with human Presenilin- and Amyloid Precursor Protein (APP). The compounds also demonstrate the ability to bind with amyloid beta (1-42) peptide. Trihydroxyflavone and its family, and arylaminoethylamide can modulate neurotransmitter release as the test compounds bind with synaptic vesicular protein VAT-1.